Multibrands Exercises Option Rights Relating to Safilo Group’s Capital Increase

By Staff
Wednesday, December 5, 2018 12:21 AM PADUA, Italy—Safilo Group S.p.A. said Tuesday afternoon that its major shareholder, Multibrands Italy BV, a subsidiary of HAL Holding NV, exercised its option rights on Monday and paid for subscription of the new shares relating to its existing holding (approximately 41.6 percent) of an ongoing capital increase. The amount involved in the exercise of the option rights totaled approximately €62.4 million, according to the Safilo announcement. Monday, Dec. 3, was the first day of the offering period and first day that Multibrands could exercise its options, under terms approved late last week by Italy’s CONSOB, as VMAIL reported.

EyeSouth Partners Continues Expansion With Georgia Eye Associates Investment

By Staff
Tuesday, November 20, 2018 12:27 AM ATLANTA—EyeSouth Partners, an eyecare-focused physician services organization formed by Shore Capital Partners,  has completed a strategic partnership with Georgia Eye Associates.

National Vision’s Secondary Offering Pricing Set

By Staff
Tuesday, November 20, 2018 12:15 AM DULUTH, Ga.—National Vision Holdings Inc. (NASDAQ: EYE) reported late last week that the public price of its previously announced secondary offering will be $40.50 per share.

National Vision Reports 67th Straight Quarter of Same-Store Sales Growth

By Staff
Wednesday, November 14, 2018 12:24 AM DULUTH, Ga.—National Vision Holdings Inc. (NASDAQ: EYE) reported Tuesday that its sales rose 11.9 percent to $387.4 million in the third quarter, which ended Sept. 29. The increase was driven, in part, by a same-store sales increase of 7 percent (6.8 percent on an adjusted basis), which marked the 67th consecutive quarter of positive comparable-store sales growth for National Vision, according to an announcement from the company. Sales in the year-ago quarter totaled $346.1 million.

New Look Reports Record Results for 3Q 2018

By Staff
Wednesday, November 14, 2018 12:21 AM MONTREAL—Canadian optical retailer New Look Vision Group (TSX: BCI) reported record results for the third quarter ended Sept. 29, 2018. Revenues increased by 32.0 percent over last year to $72.9 million, mainly as a result of New Look’s acquisition of the Iris group in 2017, as well as comparable store sales growth. Comparable store sales orders rose 0.2 percent compared to the third quarter of last year, marking New Look’s 17th consecutive quarter of comparable store sales growth.

Clearside Biomedical Reports Loss for Third Quarter and Provides Pipeline Update

By Staff
Tuesday, November 13, 2018 12:21 AM ALPHARETTA, Ga.—Clearside Biomedical Inc. (NASDAQ: CLSD), a biopharmaceutical company that develops treatments that restore and preserve vision, reported a net loss for the third quarter of $23.9 million. This compared with a net loss of $18.3 million for the third quarter of 2017. The increase in net loss was “primarily attributable to higher R&D expenses in the third quarter of 2018,” the company said in an announcement last week. The company reported no revenue for its third quarter, which ended Sept. 30.

Eye Health America Acquires Updegraff Laser Vision to Expand Southeast Presence

By Staff
Wednesday, November 7, 2018 12:24 AM ATLANTA—Eye Health America (EHA), an eyecare practice management company formed last year, has acquired Tampa Bay, Fla.-based Updegraff Laser Vision.

Bausch Health Reports ‘Organic’ Sales Growth Across All Business Segments

By Staff
Wednesday, November 7, 2018 12:21 AM LAVAL, Quebec—Bausch Health Companies (NYSE/TSX: BHC) reported Tuesday that its revenues totaled $2.14 billion in the third quarter, a decline of 4 percent ($83 million) compared with $2.22 billion in the year-ago period.

Allergan Reports Third Quarter Results Showing ‘Momentum’ in Core Business

By Staff
Wednesday, October 31, 2018 12:24 AM DUBLIN—Allergan plc (NYSE: AGN) reported Tuesday that its third quarter net revenues decreased 3 percent to $3.91 billion compared with the year-ago quarter as the loss of patent exclusivity on some brands weighed on top-line sales. The company also raised its full year sales and income guidance as sales of its “top-promoted products”—including Botox, Vraylar, Juvederm, Loestrin and Alloderm—are expected to drive revenue performance, according to the announcement. Sales of Restasis, a treatment for dry eye, declined 18.8 percent in the third quarter to $298.0 million, although the drop-off in sales during the quarter “were not as severe due to a delay in the launch of cheaper copycats of the dry eye treatment,” according to a Reuters report.

Update: Philadelphia-Based Vantage EyeCare Announces Addition of Three New Divisions

By Staff
Tuesday, October 30, 2018 12:24 AM PHILADELPHIA—Vantage EyeCare LLC, which was formed earlier this year with the intention of becoming the largest, private ophthalmology group in Pennsylvania, New Jersey and Delaware, has added three eyecare companies to its operations, according to an announcement Friday.

Safilo Group Confirms Execution of New €150 Million Financing Agreement

By Staff
Tuesday, October 30, 2018 12:21 AM PADUA, Italy—Safilo Group S.p.A.  confirmed on Monday a comprehensive refinancing plan announced on Sept. 26 this year, as VMAIL previously reported.

Essilor Posts 4.4 Percent Rise in 3Q Revenue

By Staff
Tuesday, October 23, 2018 12:30 AM CHARENTON-LE-PONT, France—EssilorLuxottica (Euronext Paris: EL), Essilor International’s new corporate name since it combined with Luxottica Group S.p.A. (MTA: LUX) on Oct., 1, 2018, posted a 4.4 percent increase in revenue, up 5 percent like-for-like, to €1.8 billion.

Luxottica's Q3 Net Sales Rise 3.5 Percent

By Staff
Tuesday, October 23, 2018 12:27 AM MILAN—Third quarter net sales for Luxottica Group S.p.A. (MTA: LUX) grew by 3.5 percent at constant exchange rates and 2.9 percent at current rates, driven by retail and e-commerce, the company reported.

J&J Reports 3.6 Percent Sales Increase in Q3 as Vision Care Turns in a Solid Performance

By Staff
Wednesday, October 17, 2018 12:24 AM NEW BRUNSWICK, N.J.—Johnson & Johnson (NYSE: JNJ), citing a strong performance across its pharmaceutical business, as well as a solid performance from the U.S. vision care segment, reported Tuesday that third-quarter sales rose 3.6 percent to $20.3 billion. Operational sales (which exclude currency factors) increased 5.5 percent, while domestic sales increased 3.6 percent. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 6.1 percent, domestic sales increased 3.9 percent and international sales increased 8.5 percent, according to J&J’s announcement.

SightMD Announces ‘Partnership’ With Mid Island Eye Physicians & Surgeons

By Staff
Wednesday, October 17, 2018 12:21 AM HAUPPAUGE, N.Y.—SightMD, a leading multi-specialty ophthalmology platform and a portfolio company of Chicago Pacific Founders, has announced a strategic partnership with Mid Island Eye Physicians & Surgeons. The partnership adds five physicians and one location in Bethpage, N.Y., to SightMD’s team of more than 50 physicians working across 25 locations in New York, according to the announcement. SightMD is backed by Chicago Pacific Founders, a leading middle-market private equity firm that focuses exclusively on partnerships with companies in health care services.